Alignment Healthcare (NASDAQ:ALHC) Stock Price Target Cut by JPMorgan Chase & Co.

Alignment Healthcare (NASDAQ:ALHC) had its target price dropped by research analysts at JPMorgan Chase & Co. from $10.00 to $8.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 10.04% from the stock’s current price.

A number of other analysts have also recently issued reports on ALHC. KeyCorp cut Alignment Healthcare from an “overweight” rating to a “sector weight” rating in a research note on Friday. William Blair cut shares of Alignment Healthcare from an “outperform” rating to a “market perform” rating in a research report on Friday, October 9th. Needham & Company LLC started coverage on shares of Alignment Healthcare in a research note on Wednesday. They issued a “hold” rating for the company. Wall Street Zen cut Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Raymond James Financial reissued an “outperform” rating on shares of Alignment Healthcare in a research note on Monday, October 12th. Six investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.27.

Alignment Healthcare Trading Down 9.8%

ALHC stock traded down $0.79 during midday trading on Friday, hitting $7.27. 13,820,261 shares of the company’s stock were exchanged, compared to its average volume of 5,666,000. Alignment Healthcare has a one year low of $6.01 and a one year high of $25.12. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.70 and a current ratio of 1.70. The company has a market cap of $1.51 billion, a PE ratio of 38.27 and a beta of 1.14. The stock’s fifty day moving average price is $9.99 and its 200-day moving average price is $16.89.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.31 billion. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%. The company’s revenue for the quarter was up 36.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.02 earnings per share. Research analysts predict that Alignment Healthcare will post 0.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Alignment Healthcare

In other Alignment Healthcare news, insider Hyong Kim sold 32,479 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $8.30, for a total transaction of $269,575.70. Following the sale, the insider directly owned 299,271 shares of the company’s stock, valued at $2,483,949.30. The trade was a 9.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John E. Kao sold 385,270 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $12.68, for a total transaction of $4,885,223.60. Following the transaction, the chief executive officer owned 1,223,473 shares of the company’s stock, valued at approximately $15,513,637.64. This represents a 23.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,061,967 shares of company stock worth $13,642,490 in the last three months. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alignment Healthcare

Several hedge funds have recently modified their holdings of ALHC. Bank of America Corp DE raised its holdings in Alignment Healthcare by 156.5% during the first quarter. Bank of America Corp DE now owns 3,215,667 shares of the company’s stock worth $56,660,000 after acquiring an additional 1,961,778 shares in the last quarter. Formula Growth Ltd. acquired a new position in Alignment Healthcare during the second quarter valued at approximately $5,270,000. Bank of New York Mellon Corp bought a new position in Alignment Healthcare in the second quarter valued at approximately $87,077,000. Principal Financial Group Inc. grew its stake in Alignment Healthcare by 36.5% in the first quarter. Principal Financial Group Inc. now owns 544,274 shares of the company’s stock valued at $9,590,000 after purchasing an additional 145,491 shares in the last quarter. Finally, Corient Private Wealth LP bought a new position in Alignment Healthcare in the second quarter valued at approximately $3,247,000. Institutional investors own 86.19% of the company’s stock.

Alignment Healthcare News Roundup

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Alignment reported third-quarter revenue of $1.36 billion, up 36.7% year over year and above the $1.31 billion analyst estimate. Adjusted EPS of a $0.04 loss matched consensus. Alignment Healthcare Reports Third Quarter 2026 Results
• Positive Sentiment: Management is targeting at least 20% top-line growth in 2027, supporting the company’s longer-term expansion narrative. Alignment Targets 2027 Growth
• Neutral Sentiment: Barclays reduced its price target from $10 to $9 while maintaining an “equal weight” rating, implying potential upside but limited conviction. Barclays Rating
• Negative Sentiment: Alignment lowered its 2026 adjusted EBITDA outlook to at least $100 million, signaling weaker near-term profitability and helping offset the revenue beat. Alignment EBITDA Outlook
• Negative Sentiment: CMS reduced the 2027 Star Rating for Alignment’s California HMO contract H3815 from 4.0 to 3.5 stars. The contract serves approximately 75% of membership, raising concerns about bonus eligibility, enrollment and reimbursement economics. Alignment H3815 CMS Rating Concerns
• Negative Sentiment: KeyCorp downgraded ALHC from “overweight” to “sector weight,” while multiple law firms announced investigations into possible securities-law violations. These notices are allegations and do not establish wrongdoing, but they add reputational and legal overhang. Alignment Investigation Notice

Alignment Healthcare Company Profile

Alignment Healthcare, Inc is a technology-enabled health insurance company focused on providing Medicare Advantage plans for seniors. The company combines health plan coverage with care coordination and clinical services designed to help members manage chronic conditions, access providers and navigate the health care system.

Its offerings include Medicare Advantage plans, supplemental benefits and member support services. Alignment also uses its proprietary technology platform, including the Alignment Virtual Application (AVA), to support care teams, analyze health information and help deliver more personalized services to members.

Founded in 2013, Alignment Healthcare serves Medicare-eligible consumers in selected markets, including California, Florida, Nevada and North Carolina.